Advertisement
Table 1 Patient characteristics
| Parameter | Value |
|---|---|
| Total number of patients | 52 |
| Age, years (mean ± SD) | 71.5 ± 9 |
| PSA at first PET/CT (ng/ml), median (IQR) | 6.6 (1.3–28.3) |
| PSA at second PET/CT (ng/ml), median (IQR) | 1.6 (0.3–12.1) |
| Gleason score (n) | |
| 6 | 6 (11.5%) |
| 7 | 2 (3.8%) |
| 7 (3 + 4) | 8 (15.4%) |
| 7 (4 + 3) | 6 (11.5%) |
| 8 | 9 (17.3%) |
| 9 | 12 (23.1%) |
| 10 | 2 (3.8%) |
| n/a | 7 (13.5%) |
| Disease extent demonstrated on first PET/CT (n) | |
| Prostatic disease | 29 (55.8%) |
| Bone metastases | 32 (61.5%) |
| Lymph nodes | 42 (80.8%) |
| Liver metastases | 2 (3.8%) |
| Peritoneal implants | 2 (3.8%) |
| Lung metastases | 1 (1.9%) |
| Treatment received between the two PET/CT scans (n) | |
| Hormonal therapy | 42 (80.8%) |
| Salvage radiotherapy | 17 (32.7%) |
| Chemotherapy | 12 (23.1%) |
| Radium-223 | 2 (3.8%) |
